June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
Effect of combined treatment of diabetic macular edema on macular ischemia
Author Affiliations & Notes
  • Alexandros Deligiannidis
    CHUVI Vigo, Vigo, Spain
  • Jose Lorenzo Carrero
    POVISA Hospital, VIGO, Spain
  • Ines Perez Flores
    POVISA Hospital, VIGO, Spain
  • Theodore Paraskevopoulos
    “G. Gennimatas” General Hospital of Athens, Athens, Greece
  • Pilar Bolivar Montesa
    CHUVI Vigo, Vigo, Spain
  • Footnotes
    Commercial Relationships Alexandros Deligiannidis, None; Jose Lorenzo Carrero, None; Ines Perez Flores, None; Theodore Paraskevopoulos, None; Pilar Bolivar Montesa, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2374. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Alexandros Deligiannidis, Jose Lorenzo Carrero, Ines Perez Flores, Theodore Paraskevopoulos, Pilar Bolivar Montesa; Effect of combined treatment of diabetic macular edema on macular ischemia. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2374. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To evaluate the effect of treatment on macular ischemia in patients with diabetic macular edema.

Methods: Twenty-seven eyes from 15 patients diagnosed of diabetic macular edema were included in the study. A comprehensive ophthalmologic examination was performed. All patients underwent a digital high-resolution fluorescein angiography with a laser confocal ophthalmoscope (SPECTRALIS HRA2+OCT), followed by a Spectral-Domain OCT examination with active eye tracking at the beginning and at the conclusion of the study. Patients were treated either with intravitreal injections of bevacizumab, with focal laser or with a combination of both. The mean follow-up period was 15 months. The ischemia was quantified with a computer-assisted image analysis software. Data from one eye of each patient were assessed with the T-test for paired samples.

Results: Of the eyes treated, 27% received only intravitreal injections of bevacizumab, 20% only focal laser and 53% a combination of both. The mean number of injections for each eye treated with bevacizumab was 2.25. In all three treatment groups, there was no significant change observed in macular ischemia (p=0,201, p=0,213, p=0,688). In all three groups, the visual acuity (VA) did not change significantly (p=0,215, p=0,523, p=0,810). The mean foveal thickness (FT) decreased statistically significantly in the groups that received treatment with intravitreal injections of bevacizumab, alone or combined with focal laser, but not in the focal laser-alone group (p=0,05, p=0,05, p=0,427).

Conclusions: The macular ischemia was not altered after repeated intravitreal injections of bevacizumab, focal laser treatment or a combination of both.

Keywords: 498 diabetes • 505 edema • 572 ischemia  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.